Recent Updates — TTRX
Turn Therapeutics Inc. filed an 8-K to furnish an updated corporate investor presentation dated October 6, 2026. The filing discloses that the company holds approximately $10.3 million in cash as of June 30, 2026, with a runway extending into Q3 2027 and access to additional capital under existing facilities. The presentation details interim Phase 2 data for GX-03 in moderate-to-severe atopic dermatitis (AD), noting statistically significant treatment separation over vehicle controls in key efficacy endpoints such as vIGA-AD success and EASI-75 improvement. Topline results for the AD trial are expected in Q1 2027, with Phase 3 initiation planned subsequently. The company also outlined pipeline milestones for GX-03 in onychomycosis (Phase 3 ready) and hidradenitis suppurativa (Phase 2a initiation planned). Turn Therapeutics is a biotechnology company developing precision immunomodulation therapies targeting inflammatory skin diseases.
Turn Therapeutics Inc. appointed Robert R. Redfield, M.D., as Chief Scientific Officer on September 9, 2026. Dr. Redfield brings over four decades of experience in immunology and public health, including service as the former Director of the U.S. Centers for Disease Control and Prevention. In this role, he will contribute to the scientific strategy for lead candidate GX-03 across indications such as atopic dermatitis, onychomycosis, and hidradenitis suppurativa. Turn Therapeutics Inc. is a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases.
Turn Therapeutics Inc. issued 579,664 shares of common stock to GEM Yield Bahamas Limited on August 13, 2026, following the full cashless exercise of a warrant for 1,192,207 shares. The transaction relied on Section 4(a)(2) registration exemption based on the investor's accredited status. Turn Therapeutics Inc. operates in the biotechnology industry, focusing on drug discovery and development.
On August 14, 2026, Turn Therapeutics Inc. entered into securities purchase agreements with accredited investors to issue and sell 135,000 shares of common stock at $10.00 per share, generating aggregate gross proceeds of $1.35 million. The transaction was conducted as a private placement under Section 4(a)(2) of the Securities Act and Regulation D, with registration rights granted to the investors. Turn Therapeutics Inc. operates in the biotechnology industry, focusing on drug discovery and development.
Turn Therapeutics Inc. reported financial and operating results for the quarter ended June 30, 2026. The company announced that interim Phase 2 data for its lead candidate GX-03 in atopic dermatitis showed activity across a broader patient population than anticipated, prompting an expansion of Stage 2 enrollment to approximately 120–135 patients with moderate-to-severe lesions but lower overall disease extent. Turn Therapeutics appointed former FDA Commissioner Dr. Stephen M. Hahn as Executive Clinical and Regulatory Lead on May 18, 2026. Financially, the company reported a net loss of $5.8 million for the quarter, with cash and cash equivalents totaling $10.3 million as of June 30, 2026, providing operational runway into the third quarter of 2027. The company also plans to expand GX-03 development into hidradenitis suppurativa, targeting first patient dosing in Q2 2027. Turn Therapeutics is a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases.